Progress of Legumain in malignant tumors

doi:10.3760/cma.j.cn371439-20200527-00075

Abstract

Abstract:

Legumain, also called asparaginyl endopeptidase, is one new member of the cysteine protease C13 family and plays various roles in human. In recent years, studies have displayed that Legumain is over expressed in a variety of tumors types and promotes the proliferation of tumor cells, tumor invasion and metastasis as well as angiogenesis through varied mechanisms. Further investigation of Legumain will be helpful to elucidate the pathogenesis and progression mechanism of malignant tumors and provide new molecular for targeted therapy of tumors.

Key words: Neoplasms, Molecular targeted therapy, Mechanism, Legumain

Yan Bingfang, Meng Wei, Bai Xuelian. Progress of Legumain in malignant tumors[J]. Journal of International Oncology, 2020, 47(9): 546-549.

References 36

[1]	Kembhavi AA, Buttle DJ, Knight CG, et al. The two cysteine endopeptidases of legume seeds: purification and characterization by use of specific assays[J]. Arch Biochem Biophys, 1993,303(2):208-213. DOI: 10.1006/abbi.1993.1274. doi: 10.1006/abbi.1993.1274 pmid: 8512309
[2]	Liu C, Sun C, Huang H, et al. Overexpression of Legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy[J]. Cancer Res, 2003,63(11):2957-2964. DOI: 10.1097/00002820-200306000-00012. pmid: 12782603
[3]	Dall E, Brandstetter H. Structure and function of Legumain in health and disease[J]. Biochimie, 2016,122:126-150. DOI: 10.1016/j.biochi.2015.09.022. doi: 10.1016/j.biochi.2015.09.022 pmid: 26403494
[4]	Lunde NN, Haugen MH, Bodin Larsen KB, et al. Glycosylation is important for Legumain localization and processing to active forms but not for cystatin E/M inhibitory functions[J]. Biochimie, 2017,139:27-37. DOI: 10.1016/j.biochi.2017.05.009. doi: 10.1016/j.biochi.2017.05.009 pmid: 28528272
[5]	Lin S, Li T, Xie P, et al. Targeted delivery of doxorubicin to tumour tissues by a novel Legumain sensitive polygonal nanogel[J]. Nanoscale, 2016,8(43):18400-18411. DOI: 10.1039/c6nr05870a. doi: 10.1039/c6nr05870a pmid: 27774557
[6]	Jafari A, Qanie D, Andersen TL, et al. Legumain regulates differentiation fate of human bone marrow stromal cells and is altered in postmenopausal osteoporosis[J]. Stem Cell Reports, 2017,8(2):373-386. DOI: 10.1016/j.stemcr.2017.01.003. doi: 10.1016/j.stemcr.2017.01.003 pmid: 28162997
[7]	Hasegawa S, Inoue D, Yamasaki M, et al. Site-specific cleavage of acetoacetyl-CoA synthetase by Legumain[J]. FEBS Lett, 2016,590(11):1592-1601. DOI: 10.1002/1873-3468.12197. doi: 10.1002/1873-3468.12197 pmid: 27129883
[8]	Anderson BM, de Almeida LGN, Sekhon H, et al. N-terminomics/TAILS profiling of macrophages after chemical inhibition of Legumain[J]. Biochemistry, 2019,59(3):329-340. DOI: 10.1021/acs.biochem.9b00821. doi: 10.1021/acs.biochem.9b00821 pmid: 31774660
[9]	Wang D, Xiong M, Chen C, et al. Legumain, an asparaginyl endopeptidase, mediates the effect of M2 macrophages on attenuating renal interstitial fibrosis in obstructive nephropathy[J]. Kidney Int, 2018,94(1):91-101. DOI: 10.1016/j.kint.2017.12.025. doi: 10.1016/j.kint.2017.12.025 pmid: 29656902
[10]	Meng F, Liu W. Knockdown of Legumain suppresses cervical cancer cell migration and invasion[J]. Oncol Res, 2016,23(1):7-12. DOI: 10.3727/096504015X14410238486649. doi: 10.3727/096504015X14410238486649 pmid: 29021015
[11]	Wu T, Sun L, Wu Y, et al. Prognostic value of Legumain in uveal melanoma[J]. Mol Med Rep, 2016,13(3):2377-2384. DOI: 10.3892/mmr.2016.4838. doi: 10.3892/mmr.2016.4838 pmid: 26846877
[12]	Haugen MH, Boye K, Nesland JM, et al. High expression of the cysteine proteinase Legumain in colorectal cancer-implications for therapeutic targeting[J]. Eur J Cancer, 2015,51(1):9-17. DOI: 10.1016/j.ejca.2014.10.020. doi: 10.1016/j.ejca.2014.10.020 pmid: 25466510
[13]	Wang H, Chen B, Lin Y, et al. Legumain promotes gastric cancer progression through tumor-associated macrophages in vitro and in vivo[J]. Int J Biol Sci, 2020,16(1):172-180. DOI: 10.7150/ijbs.36467. doi: 10.7150/ijbs.36467 pmid: 31892854
[14]	Luo M, Li Q, Wang D, et al. Fabrication of chitosan based nanocomposite with Legumain sensitive properties using charge driven self-assembly strategy[J]. J Mater Sci Mater Med, 2018,29(9):142. DOI: 10.1007/s10856-018-6149-y. doi: 10.1007/s10856-018-6149-y pmid: 30121849
[15]	Zhang M, Jiang Z, Chen S, et al. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design[J]. Chem Biol Drug Des, 2018,91(2):534-544. DOI: 10.1111/cbdd.13116. doi: 10.1111/cbdd.13116 pmid: 28994241
[16]	Wang L, Chen S, Zhang MN, et al. Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer[J]. J Cell Biochem, 2012,113(8):2679-2686. DOI: 10.1002/jcb.24143. doi: 10.1002/jcb.24143 pmid: 22441772
[17]	杜祎祎. Legumain通过PI3K/AKT通路促进乳腺癌侵袭和转移的研究[D]. 天津: 天津医科大学, 2019. DOI: 10.27366/d.cnki.gtyku.2019.000313.
[18]	Murthy RV, Arbman G, Gao J, et al. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer[J]. Clin Cancer Res, 2005,11(6):2293-2299. DOI: 10.1158/1078-0432.ccr-04-1642. doi: 10.1158/1078-0432.CCR-04-1642 pmid: 15788679
[19]	Zhen Y, Chunlei G, Wenzhi S, et al. Clinicopathologic significance of Legumain overexpression in cancer: a systematic review and meta-analysis[J]. Sci Rep, 2015,5:16599. DOI: 10.1038/srep16599. doi: 10.1038/srep16599 pmid: 26607955
[20]	Toss MS, Miligy IM, Gorringe KL, et al. Legumain is an indepen-dent predictor for invasive recurrence in breast ductal carcinoma in situ[J]. Mod Pathol, 2019,32(5):639-649. DOI: 10.1038/s41379-018-0180-x. doi: 10.1038/s41379-018-0180-x pmid: 30429518
[21]	Shen L, Li H, Shi Y, et al. M2 tumour-associated macrophages contribute to tumour progression via Legumain remodelling the extracellular matrix in diffuse large B cell lymphoma[J]. Sci Rep, 2016,6:30347. DOI: 10.1038/srep30347. doi: 10.1038/srep30347 pmid: 27464733
[22]	Andrade V, Guerra M, Jardim C, et al. Nucleoplasmic calcium regulates cell proliferation through Legumain[J]. J Hepatol, 2011,55(3):626-635. DOI: 10.1016/j.jhep.2010.12.022. doi: 10.1016/j.jhep.2010.12.022 pmid: 21237226
[23]	Liu Y, Goswami RK, Liu C, et al. Chemically programmed bispecific antibody targeting Legumain protease and αvβ3 integrin mediates strong antitumor effects[J]. Mol Pharm, 2015,12(7):2544-2550. DOI: 10.1021/acs.molpharmaceut.5b00257. doi: 10.1021/acs.molpharmaceut.5b00257 pmid: 26024761
[24]	Cui Y, Wang Y, Li H, et al. Asparaginyl endopeptidase promotes the invasion and metastasis of gastric cancer through modulating epithelial-to-mesenchymal transition and analysis of their phosphorylation signaling pathways[J]. Oncotarget, 2016,7(23):34356-34370. DOI: 10.18632/oncotarget.8879. doi: 10.18632/oncotarget.8879 pmid: 27102302
[25]	Zhang Y, Wu YY, Jiang JN, et al. MiRNA-3978 regulates peritoneal gastric cancer metastasis by targeting Legumain[J]. Oncotarget, 2016,7(50):83223-83230. DOI: 10.18632/oncotarget.12917. doi: 10.18632/oncotarget.12917 pmid: 27793040
[26]	Yamane T, Murao S, Kato-Ose I, et al. Transcriptional regulation of the legumain gene by p53 in HCT116 cells[J]. Biochem Biophys Res Commun, 2013,438(4):613-618. DOI: 10.1016/j.bbrc.2013.08.007. doi: 10.1016/j.bbrc.2013.08.007 pmid: 23942113
[27]	Yamane T, Yamamoto Y, Nakano Y, et al. Expression and protease activity of mouse Legumain are regulated by the oncogene/transcription co-activator, DJ-1 through p53 and cleavage of annexin A2 is increased in DJ-1-knockout cells[J]. Biochem Biophys Res Commun, 2015,467(3):472-477. DOI: 10.1016/j.bbrc.2015.10.032. doi: 10.1016/j.bbrc.2015.10.032 pmid: 26462467
[28]	Yamane T, Kato-Ose I, Sakamoto T, et al. Secretion of Legumain increases in conditioned medium from DJ-1-knockout cells and in serum from DJ-1-knockout mice[J]. Open Biochem J, 2018,12:29-35. DOI: 10.2174/1874091X01812010029. doi: 10.2174/1874091X01812010029 pmid: 29541256
[29]	Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors[J]. Nucleic Acids Res, 2012,40:D343-D350. DOI: 10.1093/nar/gkt987. doi: 10.1093/nar/gkr987 pmid: 22086950
[30]	Yamane T, Kozuka M, Yamamoto Y, et al. Protease activity of Legumain is inhibited by an increase of cystatin E/M in the DJ-1-knockout mouse spleen, cerebrum and heart[J]. Biochem Biophys Rep, 2017,9:187-192. DOI: 10.1016/j.bbrep.2016.12.010. doi: 10.1016/j.bbrep.2016.12.010 pmid: 28956004
[31]	Lerchen HG, Stelte-Ludwig B, Berndt S, et al. Antibodye-prodrug conjugates with ksp inhibitors and Legumain-mediated metabolite formation[J]. Chemistry, 2019,25(35):8208-8213. DOI: 10.1002/chem.201900441. pmid: 30869180
[32]	Shi T, Gu L, Sun Y, et al. Enhanced Legumain-recognition and NIR controlled released of cisplatin-indocyanine nanosphere against gastric carcinoma[J]. Eur J Pharmacol, 2017,794:184-192. DOI: 10.1016/j.ejphar.2016.11.039. doi: 10.1016/j.ejphar.2016.11.039 pmid: 27894812
[33]	Li Y, Niu Y, Zhu J, et al. Tailor-made Legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release[J]. Nanoscale, 2020,12(4):2673-2685. DOI: 10.1039/c9nr08558k. doi: 10.1039/C9NR08558K pmid: 31942900
[34]	Eddie SL, Gregson A, Graham E, et al. Identification and SAR exploration of a novel series of Legumain inhibitors[J]. Bioorg Med Chem Lett, 2019,29(12):1546-1548. DOI: 10.1016/j.bmcl.2019.03.019. doi: 10.1016/j.bmcl.2019.03.019 pmid: 31005445
[35]	Li X, Liu Q, Ye S, et al. A protease-responsive fluorescent probe for sensitive imaging of Legumain activity in tumor cells[J]. Chem Biol Drug Des, 2019,94(2):1494-1503. DOI: 10.1111/cbdd.13530. doi: 10.1111/cbdd.13530 pmid: 31002467
[36]	Zhao Y, Hai Z, Wang H, et al. Legumain-specific near-infrared fluorescence “turn on” for tumor-targeted imaging[J]. Anal Chem, 2018,90(15):8732-8735. DOI: 10.1021/acs.analchem.8b02704. doi: 10.1021/acs.analchem.8b02704 pmid: 30027744